Other
Uterine Fibroid
47
Pipeline Programs↗
9
Active Trials↗
28
Companies Involved↗
Uterine Fibroid is a moderately active landscape with 47 programs across 28 companies. The most active players are ACADIA Pharmaceuticals Inc., Laboratoire français de Fractionnement et de Biotechnologies, Repros Therapeutics Inc.. 16 therapies are approved with 13 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical5
Phase 13
Phase 210
Phase 313
Analysis
Trial Status
82
clinical trials
Completed48 · 59%
Terminated18 · 22%
Recruiting7 · 9%
Unknown status4 · 5%
Withdrawn3 · 4%
Active, not recruiting1 · 1%
Other1 · 1%
Clinical Trials
Trial Activity
82 trials
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)